Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Immucor, Inamed in human collagen deal

This article was originally published in Clinica

Executive Summary

Norcross, Virginia-based Immucor is to develop human collagen mesh jointly with Inamed under an agreement signed between the companies on March 20. Immucor's subsidiary, Gamma Biologicals, which specialises in human cell line growth, will optimise the manufacturing process for the production of human raw collagen for Inamed. The collaboration will have two stages, with both companies hoping to enter a supply agreement after the development stage is completed. Immucor president Edward Gallup said his company had excess capacity at its production facility and "years of expertise" in growing human cell lines. Inamed made $74m in sales of dermal fillers in 2002.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT061562

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel